Integrated Investment Consultants LLC Sells 314 Shares of AbbVie Inc. (NYSE:ABBV)
Integrated Investment Consultants LLC lessened its stake in AbbVie Inc. (NYSE:ABBV) by 3.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,520 shares of the company’s stock after selling 314 shares during the period. Integrated Investment Consultants LLC’s holdings in AbbVie were worth $834,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of the stock. Element Wealth LLC grew its holdings in AbbVie by 5.7% during the 2nd quarter. Element Wealth LLC now owns 5,524 shares of the company’s stock worth $542,000 after acquiring an additional 296 shares during the period. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC grew its holdings in AbbVie by 7.0% during the 2nd quarter. Genovese Burford & Brothers Wealth & Retirement Plan Management LLC now owns 2,948 shares of the company’s stock worth $289,000 after acquiring an additional 193 shares during the period. Wesbanco Bank Inc. grew its holdings in AbbVie by 72.8% during the 2nd quarter. Wesbanco Bank Inc. now owns 128,245 shares of the company’s stock worth $12,591,000 after acquiring an additional 54,010 shares during the period. Banco Santander S.A. grew its holdings in AbbVie by 664.9% during the 2nd quarter. Banco Santander S.A. now owns 118,133 shares of the company’s stock worth $11,599,000 after acquiring an additional 102,689 shares during the period. Finally, Laidlaw Wealth Management LLC grew its holdings in shares of AbbVie by 74.7% in the 2nd quarter. Laidlaw Wealth Management LLC now owns 7,671 shares of the company’s stock valued at $753,000 after buying an additional 3,280 shares during the period. Hedge funds and other institutional investors own 68.23% of the company’s stock.
NYSE:ABBV traded down $2.13 on Wednesday, hitting $80.58. 485,256 shares of the company’s stock were exchanged, compared to its average volume of 9,647,154. The firm has a 50-day moving average price of $87.44 and a 200-day moving average price of $91.02. The company has a debt-to-equity ratio of 5.57, a current ratio of 0.86 and a quick ratio of 0.70. AbbVie Inc. has a 52 week low of $62.55 and a 52 week high of $101.28. The company has a market cap of $145.97 billion, a P/E ratio of 17.19, a price-to-earnings-growth ratio of 1.40 and a beta of 0.74.
The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $1.18 per share. The ex-dividend date is Wednesday, October 14th. This represents a $4.72 annualized dividend and a yield of 5.86%. AbbVie’s dividend payout ratio (DPR) is presently 52.80%.
Several equities analysts have recently issued reports on ABBV shares. Citigroup boosted their price target on shares of AbbVie from $98.00 to $105.00 and gave the company a “buy” rating in a report on Wednesday, September 2nd. JPMorgan Chase & Co. boosted their price target on shares of AbbVie from $115.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, October 16th. Morgan Stanley boosted their price target on shares of AbbVie from $95.00 to $108.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. The Goldman Sachs Group lowered shares of AbbVie from a “neutral” rating to a “sell” rating in a report on Tuesday, October 20th. Finally, Berenberg Bank started coverage on shares of AbbVie in a report on Tuesday, September 29th. They issued a “hold” rating and a $98.00 price target for the company. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $108.71.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal BehÃ§et's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrÃ¶m's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Further Reading: How is an ETF different from a mutual fund?
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.